132 related articles for article (PubMed ID: 35504658)
41. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
Dowty ME; Qiu R; Dantonio A; Niosi M; Doran A; Balesano A; Wright SW; Walker GS; Sharma R
Drug Metab Dispos; 2024 Jun; 52(7):690-702. PubMed ID: 38719744
[TBL] [Abstract][Full Text] [Related]
42. Absorption, Distribution, Metabolism, and Excretion of [
Dahal UP; Rock BM; Rodgers J; Shen X; Wang Z; Wahlstrom JL
Drug Metab Dispos; 2022 May; 50(5):600-612. PubMed ID: 35153196
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract][Full Text] [Related]
44. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
45. Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.
Yi P; Hadden C; Kulanthaivel P; Calvert N; Annes W; Brown T; Barbuch RJ; Chaudhary A; Ayan-Oshodi MA; Ring BJ
Drug Metab Dispos; 2010 Apr; 38(4):554-65. PubMed ID: 20075192
[TBL] [Abstract][Full Text] [Related]
46. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects.
Helleberg H; Bjelke M; Damholt BB; Pedersen PJ; Rasmussen MH
Eur J Pharm Sci; 2021 Dec; 167():106030. PubMed ID: 34601071
[TBL] [Abstract][Full Text] [Related]
47. Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs.
Miao Z; Scott DO; Griffith DA; Day R; Prakash C
Drug Metab Dispos; 2011 Dec; 39(12):2191-208. PubMed ID: 21875952
[TBL] [Abstract][Full Text] [Related]
48. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
[TBL] [Abstract][Full Text] [Related]
50. Disposition of [
Wickremsinhe ER; Hynes SM; Payne CD; Guo Y; Cassidy KC
Xenobiotica; 2020 Jul; 50(7):793-804. PubMed ID: 31847673
[TBL] [Abstract][Full Text] [Related]
51. Disposition and Metabolism of [
Ueno T; Ishida T; Aluri J; Suzuki M; Beuckmann CT; Kameyama T; Asakura S; Kusano K
Drug Metab Dispos; 2021 Jan; 49(1):31-38. PubMed ID: 33144331
[TBL] [Abstract][Full Text] [Related]
52. Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry.
Liu Y; Yao X; Song L; Liu H; Zhao Q; Jiang J; Ni G; Shi C; Ma X; Zhou H; Liu D; Hu P
J Pharm Biomed Anal; 2018 Aug; 157():189-200. PubMed ID: 29803910
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.
Ryder TF; Bergman A; King-Ahmad A; Amin NB; Lall MS; Ballard TE; Kalgutkar AS
Xenobiotica; 2022 Mar; 52(3):240-253. PubMed ID: 35382680
[TBL] [Abstract][Full Text] [Related]
54. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent
Ma S; Cho S; Sahasranaman S; Zhao W; Pang J; Ding X; Dean B; Wang B; Hsu JY; Ware J; Salphati L
Drug Metab Dispos; 2023 Apr; 51(4):436-450. PubMed ID: 36623882
[TBL] [Abstract][Full Text] [Related]
55. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
[TBL] [Abstract][Full Text] [Related]
56. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
Tiseo PJ; Perdomo CA; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
[TBL] [Abstract][Full Text] [Related]
57. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
58. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman JN; Doran AC; King-Ahmad A; Sharma R; Walker GS; Lin J; Lin TH; Telliez JB; Tripathy S; Goosen TC; Banfield C; Malhotra BK; Dowty ME
Drug Metab Dispos; 2022 Aug; 50(8):1106-1118. PubMed ID: 35701182
[TBL] [Abstract][Full Text] [Related]
59. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
60. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
